 Katherine Rennie
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hair Cells, Vestibular | 22 | 2026 | 32 | 6.190 |
Why?
| | Neurons, Afferent | 6 | 2026 | 102 | 2.040 |
Why?
| | Vestibule, Labyrinth | 6 | 2026 | 91 | 2.010 |
Why?
| | Potassium | 11 | 2024 | 152 | 1.790 |
Why?
| | Potassium Channels | 8 | 2024 | 145 | 1.580 |
Why?
| | Gerbillinae | 19 | 2026 | 72 | 1.580 |
Why?
| | Action Potentials | 9 | 2023 | 506 | 1.520 |
Why?
| | Sodium | 7 | 2024 | 197 | 1.210 |
Why?
| | Hair Cells, Ampulla | 2 | 2024 | 3 | 1.180 |
Why?
| | Membrane Potentials | 13 | 2024 | 280 | 1.110 |
Why?
| | Mechanotransduction, Cellular | 3 | 2024 | 122 | 1.060 |
Why?
| | Nasal Obstruction | 3 | 2024 | 26 | 1.020 |
Why?
| | Calbindin 2 | 1 | 2026 | 12 | 0.950 |
Why?
| | Patch-Clamp Techniques | 13 | 2024 | 289 | 0.890 |
Why?
| | Ear, Inner | 2 | 2016 | 51 | 0.880 |
Why?
| | Sarcopenia | 2 | 2025 | 90 | 0.860 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2017 | 117 | 0.840 |
Why?
| | Fluoxetine | 1 | 2024 | 54 | 0.820 |
Why?
| | Frailty | 2 | 2025 | 194 | 0.760 |
Why?
| | Presynaptic Terminals | 3 | 2024 | 86 | 0.750 |
Why?
| | Sodium Channels | 3 | 2024 | 63 | 0.740 |
Why?
| | Metformin | 2 | 2025 | 315 | 0.740 |
Why?
| | Sodium Channel Blockers | 2 | 2020 | 24 | 0.720 |
Why?
| | Tetrodotoxin | 2 | 2020 | 40 | 0.720 |
Why?
| | Nasal Septum | 3 | 2024 | 30 | 0.720 |
Why?
| | Ion Channels | 3 | 2012 | 129 | 0.710 |
Why?
| | Vestibular Nerve | 1 | 2020 | 18 | 0.650 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2020 | 11 | 0.650 |
Why?
| | Nose Deformities, Acquired | 1 | 2020 | 3 | 0.630 |
Why?
| | Resistance Training | 1 | 2022 | 180 | 0.600 |
Why?
| | Conservative Treatment | 1 | 2020 | 44 | 0.600 |
Why?
| | Rhinoplasty | 1 | 2020 | 37 | 0.590 |
Why?
| | Receptors, AMPA | 2 | 2017 | 147 | 0.560 |
Why?
| | Semicircular Canals | 5 | 2009 | 37 | 0.550 |
Why?
| | Potassium Channel Blockers | 5 | 2014 | 47 | 0.530 |
Why?
| | 4-Aminopyridine | 7 | 2024 | 30 | 0.490 |
Why?
| | Hair Cells, Auditory | 5 | 2016 | 42 | 0.470 |
Why?
| | Aging | 2 | 2026 | 1964 | 0.470 |
Why?
| | Animals | 31 | 2026 | 38030 | 0.440 |
Why?
| | Hair Cells, Auditory, Inner | 2 | 2009 | 16 | 0.430 |
Why?
| | Neomycin | 1 | 2013 | 7 | 0.410 |
Why?
| | Gentamicins | 1 | 2013 | 51 | 0.390 |
Why?
| | Anthracenes | 3 | 2014 | 31 | 0.380 |
Why?
| | Apamin | 1 | 2011 | 4 | 0.360 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 13 | 0.350 |
Why?
| | Synapses | 2 | 2017 | 439 | 0.330 |
Why?
| | Calcium | 5 | 2011 | 1182 | 0.300 |
Why?
| | Columbidae | 7 | 2004 | 31 | 0.280 |
Why?
| | Cations | 2 | 2016 | 82 | 0.270 |
Why?
| | Ion Channel Gating | 2 | 2005 | 92 | 0.270 |
Why?
| | Cells, Cultured | 6 | 2017 | 4146 | 0.250 |
Why?
| | Cell Membrane | 2 | 2016 | 706 | 0.250 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2005 | 55 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1705 | 0.210 |
Why?
| | Decontamination | 1 | 2024 | 32 | 0.210 |
Why?
| | England | 2 | 2025 | 111 | 0.210 |
Why?
| | Physical Stimulation | 1 | 2004 | 68 | 0.200 |
Why?
| | Mammals | 2 | 2023 | 291 | 0.200 |
Why?
| | Vestibular Diseases | 1 | 2024 | 57 | 0.200 |
Why?
| | Dizziness | 1 | 2024 | 101 | 0.200 |
Why?
| | Models, Neurological | 2 | 2005 | 254 | 0.190 |
Why?
| | Male | 13 | 2026 | 72035 | 0.190 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1906 | 0.190 |
Why?
| | Double-Blind Method | 3 | 2025 | 2025 | 0.190 |
Why?
| | Electric Conductivity | 5 | 2004 | 84 | 0.170 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 623 | 0.170 |
Why?
| | Nystagmus, Pathologic | 1 | 2020 | 20 | 0.160 |
Why?
| | Female | 15 | 2025 | 77976 | 0.160 |
Why?
| | Vision, Binocular | 1 | 2020 | 47 | 0.160 |
Why?
| | Steroids, Fluorinated | 1 | 2020 | 1 | 0.160 |
Why?
| | Scotland | 1 | 2020 | 23 | 0.160 |
Why?
| | Wales | 1 | 2020 | 26 | 0.160 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2020 | 53 | 0.160 |
Why?
| | Administration, Intranasal | 1 | 2020 | 93 | 0.150 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 117 | 0.150 |
Why?
| | Eye Movements | 1 | 2020 | 92 | 0.150 |
Why?
| | Electrophysiology | 5 | 2009 | 218 | 0.150 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 402 | 0.140 |
Why?
| | Benzothiadiazines | 1 | 2017 | 2 | 0.130 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.130 |
Why?
| | Strontium | 1 | 2017 | 15 | 0.130 |
Why?
| | Nifedipine | 1 | 2017 | 27 | 0.130 |
Why?
| | Endoscopy | 1 | 2020 | 315 | 0.130 |
Why?
| | Visual Acuity | 1 | 2020 | 486 | 0.130 |
Why?
| | Dipeptides | 1 | 2017 | 57 | 0.130 |
Why?
| | Indoles | 1 | 2001 | 501 | 0.130 |
Why?
| | Quinoxalines | 1 | 2017 | 65 | 0.120 |
Why?
| | Pyridines | 1 | 2001 | 605 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 358 | 0.120 |
Why?
| | DNA, Mitochondrial | 2 | 2009 | 210 | 0.120 |
Why?
| | Ranidae | 1 | 2016 | 14 | 0.120 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 165 | 0.120 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 117 | 0.120 |
Why?
| | Chick Embryo | 1 | 2016 | 132 | 0.120 |
Why?
| | Patient Selection | 1 | 2020 | 719 | 0.120 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 60 | 0.120 |
Why?
| | Neurotransmitter Agents | 1 | 2016 | 82 | 0.120 |
Why?
| | Coculture Techniques | 1 | 2016 | 246 | 0.110 |
Why?
| | Fishes | 1 | 2016 | 108 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1379 | 0.110 |
Why?
| | Self Report | 1 | 2020 | 863 | 0.110 |
Why?
| | Birds | 1 | 2016 | 92 | 0.110 |
Why?
| | Acetylcholine | 1 | 2016 | 204 | 0.110 |
Why?
| | Calcium Channels | 1 | 2016 | 154 | 0.110 |
Why?
| | Elapid Venoms | 1 | 2014 | 13 | 0.110 |
Why?
| | Beta vulgaris | 1 | 2014 | 14 | 0.110 |
Why?
| | Quality of Life | 3 | 2024 | 3166 | 0.110 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 83 | 0.110 |
Why?
| | Phytotherapy | 1 | 2014 | 74 | 0.100 |
Why?
| | Nitrates | 1 | 2014 | 100 | 0.100 |
Why?
| | Carrier Proteins | 1 | 1997 | 736 | 0.100 |
Why?
| | Choline | 1 | 2014 | 136 | 0.100 |
Why?
| | Steroids | 2 | 2024 | 160 | 0.100 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 293 | 0.100 |
Why?
| | Age Factors | 1 | 2020 | 3313 | 0.090 |
Why?
| | Cyclic GMP | 1 | 2012 | 92 | 0.090 |
Why?
| | Saccule and Utricle | 3 | 2004 | 13 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2024 | 11643 | 0.090 |
Why?
| | Bee Venoms | 1 | 2011 | 9 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2917 | 0.090 |
Why?
| | Cyclic AMP | 1 | 2012 | 208 | 0.090 |
Why?
| | Cesium | 3 | 2000 | 20 | 0.090 |
Why?
| | Nitric Oxide | 1 | 2016 | 897 | 0.080 |
Why?
| | Adenosine Triphosphate | 1 | 1993 | 498 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2014 | 575 | 0.080 |
Why?
| | Guinea Pigs | 3 | 1997 | 159 | 0.080 |
Why?
| | Humans | 11 | 2025 | 144261 | 0.080 |
Why?
| | Animals, Newborn | 1 | 2011 | 901 | 0.070 |
Why?
| | Pyrimidines | 1 | 2012 | 532 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 93 | 0.070 |
Why?
| | Embryonic Stem Cells | 1 | 2009 | 130 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 371 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1759 | 0.070 |
Why?
| | In Vitro Techniques | 3 | 1994 | 1047 | 0.060 |
Why?
| | NADH Dehydrogenase | 1 | 2006 | 20 | 0.060 |
Why?
| | Aged | 2 | 2025 | 25850 | 0.060 |
Why?
| | Acidosis, Lactic | 1 | 2006 | 45 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1254 | 0.060 |
Why?
| | Point Mutation | 1 | 2006 | 243 | 0.060 |
Why?
| | Incubators, Infant | 1 | 2024 | 1 | 0.050 |
Why?
| | Walking Speed | 1 | 2025 | 51 | 0.050 |
Why?
| | Adult | 4 | 2024 | 40262 | 0.050 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2004 | 44 | 0.050 |
Why?
| | Tetraethylammonium Compounds | 2 | 1996 | 8 | 0.050 |
Why?
| | Hand Strength | 1 | 2025 | 143 | 0.050 |
Why?
| | Frail Elderly | 1 | 2025 | 133 | 0.050 |
Why?
| | Turtles | 1 | 2004 | 14 | 0.050 |
Why?
| | Environmental Microbiology | 1 | 2024 | 57 | 0.050 |
Why?
| | State Medicine | 1 | 2023 | 27 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2024 | 341 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2004 | 539 | 0.050 |
Why?
| | Mice | 3 | 2016 | 18329 | 0.050 |
Why?
| | Mitochondria | 1 | 2009 | 983 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2009 | 2048 | 0.040 |
Why?
| | Capsaicin | 1 | 2001 | 30 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 279 | 0.040 |
Why?
| | Obesity | 1 | 2014 | 3057 | 0.040 |
Why?
| | Rats | 1 | 2009 | 5592 | 0.040 |
Why?
| | Computer Simulation | 1 | 2005 | 1025 | 0.040 |
Why?
| | Neurons | 1 | 2009 | 1640 | 0.040 |
Why?
| | Cell Division | 1 | 2001 | 766 | 0.040 |
Why?
| | Calcium Signaling | 1 | 2001 | 251 | 0.040 |
Why?
| | Syndrome | 1 | 2020 | 380 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1983 | 0.040 |
Why?
| | Cell Separation | 3 | 1997 | 307 | 0.030 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 1997 | 9 | 0.030 |
Why?
| | Kinetics | 2 | 1997 | 1627 | 0.030 |
Why?
| | Chlorides | 1 | 1997 | 141 | 0.030 |
Why?
| | Feeder Cells | 1 | 2016 | 2 | 0.030 |
Why?
| | Species Specificity | 2 | 1997 | 574 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2024 | 6424 | 0.030 |
Why?
| | Clone Cells | 1 | 2016 | 266 | 0.030 |
Why?
| | Heterografts | 1 | 2016 | 143 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2603 | 0.030 |
Why?
| | Posture | 1 | 1996 | 196 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 454 | 0.030 |
Why?
| | Plant Preparations | 1 | 2014 | 37 | 0.030 |
Why?
| | Plant Roots | 1 | 2014 | 45 | 0.030 |
Why?
| | Beverages | 1 | 2014 | 69 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2014 | 66 | 0.030 |
Why?
| | Barium | 1 | 1994 | 27 | 0.030 |
Why?
| | Fura-2 | 1 | 1993 | 10 | 0.030 |
Why?
| | Electrodes | 1 | 1994 | 114 | 0.020 |
Why?
| | Vegetables | 1 | 2014 | 170 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1044 | 0.020 |
Why?
| | Electric Stimulation | 1 | 1994 | 276 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8243 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 1991 | 16 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6021 | 0.020 |
Why?
| | Cadmium | 1 | 1991 | 68 | 0.020 |
Why?
| | Hybrid Cells | 1 | 2009 | 49 | 0.020 |
Why?
| | Electron Transport | 1 | 2009 | 118 | 0.020 |
Why?
| | Neurogenesis | 1 | 2009 | 156 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 2009 | 290 | 0.020 |
Why?
| | Electron Transport Complex I | 1 | 2006 | 42 | 0.010 |
Why?
| | Body Mass Index | 1 | 2014 | 2420 | 0.010 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2006 | 150 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2006 | 121 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 307 | 0.010 |
Why?
| | Aortic Coarctation | 1 | 2006 | 79 | 0.010 |
Why?
| | Child, Preschool | 1 | 2020 | 11774 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2006 | 405 | 0.010 |
Why?
| | Avian Proteins | 1 | 2004 | 21 | 0.010 |
Why?
| | Cricetulus | 1 | 2004 | 118 | 0.010 |
Why?
| | CHO Cells | 1 | 2004 | 171 | 0.010 |
Why?
| | Cricetinae | 1 | 2004 | 303 | 0.010 |
Why?
| | Organ Specificity | 1 | 2004 | 312 | 0.010 |
Why?
| | Oocytes | 1 | 2004 | 178 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17009 | 0.010 |
Why?
| | Streptomycin | 1 | 2001 | 18 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2187 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22281 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 2154 | 0.010 |
Why?
| | Child | 1 | 2020 | 22537 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2929 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 2879 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2009 | 4556 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5988 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 4085 | 0.010 |
Why?
| | RNA | 1 | 2004 | 939 | 0.010 |
Why?
| | Cochlea | 1 | 1997 | 73 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 35762 | 0.010 |
Why?
| | Homeostasis | 1 | 1996 | 640 | 0.010 |
Why?
| | Infant | 1 | 2006 | 10022 | 0.010 |
Why?
|
|
Rennie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|